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Study Design
● All 3 studies were randomised, double-blind, placebo- (PBO) or active-controlled,  international, multicentre
trials. 
CV181-014 (Figure 1)
● Population: Previously treated patients (18 – 77 yrs) with T2D and inadequate glycaemic control (HbA1c
≥7.0% – ≤10.0%) on a stable dose of MET for ≥8 wks prior to screening and with fasting C-peptide 
≥1.0 ng/mL, body mass index (BMI) ≤40 kg/m2.  
● Intervention: 743 eligible patients were randomised and treated with SAXA 2.5 mg, SAXA 5 mg, SAXA 10 mg, 
or PBO in addition to their current dose of open-label (OL) MET for up to 24 wks (short-term [ST] treatment 
period). 
Figure 1. CV181-014 Study Design
CV181-039 (Figure 2)
● Population: Treatment-naïve patients (18 – 77 yrs) with T2D and inadequate glycaemic control (HbA1c ≥8.0% 
– ≤12.0%) and with fasting C-peptide ≥1.0 ng/mL, BMI ≤40 kg/m2.  
● Intervention: 1306 eligible patients were randomised and treated with SAXA 5 mg + MET, SAXA 10 mg + 
MET, SAXA 10 mg + PBO, or MET + PBO for up to 24 wks. 
– From wks 1 – 5, MET was up-titrated in 500 mg/d increments to a 2000 mg/d maximum in the SAXA 5 mg 
+ MET, SAXA 10 mg + MET, and MET + PBO treatment groups.
Figure 1. CV181-014 Study Design
Diabetes affects over 1.2 million people in Australia. Saxagliptin (SAXA) is a potent, selective dipeptidyl peptidase-
4 (DPP-4) inhibitor. Three 24-week phase 3 studies assessed efficacy and safety of SAXA as add-on to Metformin
(MET), as initial combination therapy with MET, or as add-on to the sulfonylurea (SU) glyburide (GLY) in patients 
(pts) with type 2 diabetes (T2D) and inadequate glycaemic control. In the add-on to MET study, 743 pts 
inadequately controlled on MET alone (HbA1c 7.0%–10.0%; mean baseline (BL) HbA1c 8.0%; mean T2D duration 
6.5 yrs) were randomised to SAXA or placebo (PBO) with ongoing dose of MET. In the initial combination study, 
1306 drug naïve pts (HbA1c 8.0%–12.0%; mean BL HbA1c 9.5%; mean T2D duration 1.7 yrs) were randomised to 
SAXA + MET, SAXA + PBO, or MET + PBO. In the add-on to SU study, 768 pts inadequately controlled on SU 
alone (HbA1c 7.5%–10.0%; mean BL HbA1c 8.4%; mean T2D duration 6.9 yrs) were randomised to SAXA or 
uptitrated GLY + PBO in addition to open-label GLY. Efficacy analyses used ANCOVA model. The proportion of 
patients reaching HbA1c goals used Fisher exact test. HbA1c goals were predefined for each study. In all three 
studies, statistically significantly greater proportions of SAXA-treated pts achieved HbA1c goals of <7.0% and ≤6.5% vs. control at 24 wks (Table). Twice as many pts treated with SAXA added to MET or GLY  achieved the 
HbA1c goal of <7% and ≤6.5% relative to control at 24 wks. For all three studies, the frequency of adverse events 
(AEs) was generally similar for SAXA vs. control (Table). SAXA 5 mg + MET as either add-on or initial combination 
therapy, and SAXA 5 mg + SU significantly improved glycaemic control, was well tolerated and achieved 
predefined HbA1c goals vs. control in more patients.
● For patients with type 2 diabetes (T2D), monotherapy is frequently insufficient to achieve or maintain the 
American Diabetes Association/European Association for the Study of Diabetes1 and the American Association 
of Clinical Endocrinologists2 recommended glycated haemoglobin (HbA1c) goals (<7.0% and ≤6.5%, 
respectively) in the face of progressive β-cell failure and increasing insulin resistance. 
● Metformin (MET) and sulfonylureas (SUs) are 2 of the most common first-line therapies used to treat T2D. 
● Saxagliptin (SAXA) is a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically designed for 
extended inhibition of the DPP-4 enzyme.
● Three multicenter, randomised, double-blind, 24-wk phase 3 trials assessed the efficacy and safety of SAXA as 
add-on to background MET (CV181-014), in combination with MET as initial therapy (CV181-039), or as add-on 
to the SU glyburide (GLY) (CV181-040) in patients with T2D and inadequate glycaemic control.3-5
● This report describes data for SAXA 5 mg as add-on or initial combination therapy vs control  with a focus on 
the proportion of patients reaching predefined HbA1c goals of <7.0% and ≤6.5%.
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CV181-040 (Figure 3) 
● Population: Previously treated patients (18 – 77 yrs) with T2D and inadequate glycaemic control (HbA1c ≥7.5% 
– ≤10.0%) on a submaximal dose of an SU (GLY) for ≥2 mos prior to screening and with fasting C-peptide 
≥1.0 ng/mL, BMI ≤40 kg/m2.  
● Intervention: 768 eligible patients were randomised and treated with SAXA 2.5 mg +  OL GLY 7.5 mg or SAXA 
5 mg + OL GLY 7.5 mg o.d. or PBO + blinded GLY 2.5 mg +  OL GLY 7.5 mg o.d. (total daily dose [TDD] of 
GLY, 10 mg/d) for up to 24 wks.
– Up-titration of blinded GLY (UP-GLY) was allowed in the GLY-only arm at wks 2 and 4 for mean 
fasting plasma glucose (MFPG) ≥100 mg/dL, to a maximum TDD of 15 mg (7.5 mg OL GLY + 7.5 mg 
blinded GLY).
– The dose of OL GLY could be reduced one dose step at the discretion of the investigator for patients who 
developed hypoglycaemia. 
Figure 3. CV181-040 Study Design
● Rescue Therapy: Patients were eligible for rescue therapy based on progressively strict glycaemic control 
criteria.
● Long-term Extension: Patients who completed their respective 24-wk ST treatment  period without rescue 
therapy, or those who were rescued in the first 24 wks were eligible to enter the respective LTE phase. 
Study Objectives
● All 3 studies shared the same primary and key secondary objectives. 
– Primary: Change from baseline to wk 24 in HbA1c with each SAXA combination therapy group vs the 
respective control group.
– Secondary: Changes from baseline to wk 24 with each SAXA combination therapy group vs the 
respective control group in:
• FPG  
• Percentages of patients achieving a therapeutic glycaemic response (HbA1c <7.0% for all 3 studies 
and HbA1c ≤6.5% for the SAXA given with MET as initial therapy study) 
• Postprandial glucose (PPG) response, as indicated by PPG-area under the curve (AUC) from 
0 – 180 min during an oral glucose tolerance test (OGTT)
– Safety: Assess safety and tolerability of each dose of SAXA combination therapy  administered for up to 
24 wks.
Statistical Analysis
● Efficacy analyses for continuous variables were performed using an analysis of  covariance (ANCOVA) model 
with treatment as an effect and baseline as the covariate, and utilized last-observation-carried-forward (LOCF) 
methodology. 
● Percentages of patients achieving a prespecified target glycaemic response (HbA1c <7.0% or ≤6.5%) at wk 24 
(LOCF) were compared between each combination treatment group vs the respective control group using the 
Fisher exact test. 
● Statistical analyses were performed on hypoglycaemia data (reported and confirmed) for the SAXA + SU 
study only. 
● Efficacy and safety measurements obtained after rescue were not included in any analyses.
METHODS (continued)
● In patients with type 2 diabetes, saxagliptin 5 mg + MET, as add-on or given as initial  combination therapy, and 
saxagliptin 5 mg + SU: 
– Provided clinically meaningful glycaemic improvements 
– Resulted in more patients achieving predefined HbA1c goals vs control without  significantly increasing 
hypoglycaemia
● Saxagliptin, in combination with MET or SU, was generally well tolerated.
● Saxagliptin may be a suitable combination partner for a broad range of patients with type 2 diabetes. 
CONCLUSIONS
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SU Add-on
PBO + 
UP-GLY
*P<.0001 vs PBO; †P=.0002 vs PBO; ‡P=.0117 vs PBO + UP-GLY.  UP-GLY = up-titrated glyburide.
0.1 (0.1)
9.1
4.5
76.8
−0.6 (0.1)*
22.8*
10.4‡
72.3
−2.0 (0.1) 
41.1 
29.0
58.5 
−2.5 (0.1)*
60.3*
45.3*
55.3
0.1 (0.1)
16.6
8.0
64.8
−0.7 (0.1)*
43.5*
22.0†
70.2 
Adjusted mean ∆ from 
BL in HbA1c (%), (SE)
HbA1c <7%, (%)
HbA1c ≤6.5%, (%)
Overall AEs, (%)
n=267n=253n=328n=320n=179n=191
SAXA 5 
mg + GLY
PBO + 
MET
SAXA 5 
mg + MET
PBO + 
MET
SAXA 5 mg 
+ MET
SAXA Given With MET
as Initial Therapy
MET Add-onEfficacy and Safety 
Variables at Wk 24
INTRODUCTION
*If rescue criteria were met in ST treatment period, PIO was added and patients entered LTE; PIO rescue also available in 
LTE.LTE = long-term extension; o.d. = once daily; PIO = pioglitazone.
*MET IR titration: Forced titration from 500 mg – 1000 mg at wk 1, then elective titration at wks 2, 3, 4, and 5 to achieve mean 
FPG 
<110 mg/dL (maximum MET 2000 mg total daily dose).†If rescue criteria were met in ST treatment period, PIO 15 – 45 mg 
o.d. was added and patients entered LTE; PIO rescue also available in LTE.
MET IR = metformin immediate release.
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● Demographic and baseline characteristics were generally balanced across treatment groups in the individual 
studies (Table 1). 
● Differences in baseline characteristics across studies included:
– Higher mean (SD) baseline HbA1c (all treatment arms) in treatment-naïve patients in  the SAXA given with 
MET as initial therapy study vs previously treated patients in the  add-on studies
• 9.5% (1.3%) for SAXA given with MET as initial therapy study  
• 8.0% (0.9%) for SAXA + MET and 8.4% (0.9%) for SAXA + SU studies
– Longer mean (SD) duration of diabetes (all treatment arms) in previously treated  patients in the add-on 
studies vs treatment-naïve patients in the SAXA given with  MET as initial therapy study
• 6.5 (5.1) yrs for SAXA + MET and 6.9 (5.8) yrs for SAXA + SU studies  n  1.7 (3.1) yrs for SAXA 
given with MET as initial therapy study
Efficacy
● SAXA added to MET or SU, or given with MET as initial combination therapy demonstrated statistically 
significantly greater decreases from baseline in HbA1c vs control (Table 2).
● In all 3 studies, a statistically significantly greater percentage of SAXA-treated patients achieved HbA1c goals of 
<7.0% and ≤6.5% vs control at 24 wks (Figure 4A and B). 
● More than twice as many patients treated with SAXA added to MET or SU achieved the HbA1c goals of <7.0% 
and ≤6.5% relative to control at 24 wks. 
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Figure 4A. Percentage of Patients Reaching HbA1c Goals After 24 Wks of Treatment 
With SAXA 5 mg 
HbA1c <7.0%
HbA1c <7.0%
HbA1c ≤6.5%
HbA1c ≤6.5%
SAXA Add-on to MET or SU
*P<.0001 vs PBO + MET; †P=.0002 vs PBO + MET; ‡P<.0001 vs PBO + UP-GLY; §P=.0117 vs PBO + UP-GLY.
Figure 4B. Percentage of Patients Reaching HbA1c Goals After 24 Wks of Treatment 
With SAXA 5 mg
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*P<.0001 vs MET.
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Safety
● SAXA added to MET or SU, or given with MET as initial combination therapy was  generally well tolerated. 
In all 3 studies, the frequency of adverse events (AEs) was  generally similar for SAXA vs control (Table 3).
● In the MET studies, the frequency of reported and confirmed hypoglycaemia was similar for SAXA compared 
with control. In the SU study, reported but not confirmed hypoglycaemia was higher for SAXA compared with 
control; the difference was not  statistically significant (Table 3). 
*Values are expressed as n (%).
† Reported hypoglycaemia was defined as events consistent with signs or symptoms of hypoglycaemia with or without  documented blood 
glucose levels. 
‡ Confirmed hypoglycaemia was defined by a fingerstick glucose value ≤50 mg/dL with associated symptoms. 
§ P=.1417 vs PBO + UP-GLY. 
|| P=1.0000 vs PBO + UP-GLY.
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